The expectorant medications market size is expected to generate US$ 17,648.2 million in revenue by 2024. According to projections, the market will be worth US$ 38,455.4 million in 2034. From 2024 to 2034, the market is projected to expand at a 4.3% compound annual growth rate. Respiratory conditions that may necessitate the use of expectorants include the common cold, pneumonia, and bronchitis. Expectorants may help patients with these illnesses by enhancing respiratory function and alleviating symptoms because they lessen excessive mucus production and congestion.
An increasing number of dry cough cases resulting in dry throats drives the demand for expectorant drugs in the market. With FDA approvals granted, expectorants are making significant progress on the global market. Throughout the healthcare industry, the FDA regulates and approves expectorant drugs to ensure their safety, effectiveness, and quality.
Get a Sample Copy of the Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-18502
The prevalence of coughs is expected to increase significantly, leading to increased demand for expectorant drugs. For instance, according to data released by the National Center for Biotechnology Information, cough accounted for about 8% of all consultations with primary care physicians worldwide. According to the same source, the annual incidence of cough in the general population is projected to be between 10% and 33% globally. Due to changes in dietary habits among youth and middle-class consumers, cough cases are also on the rise globally.
Key Takeaways:
- Secretion enhancers are the leading segment as drug type and held approximately 59.7% market value share in 2024.
- By product type, over-the-counter (OTC) drugs are expected to expand at a CAGR of 8.4%.
- The United States is expected to be an opportunistic market, registering a 6.8% CAGR through 2034.
- Germany to experience a CAGR of 4.5% with respect to expectorant drug sales.
- India and China to register CAGRs of 7.2% and 8.1% respectively from 2024 to 2034.
“Rising prevalence of cold and cough, coupled with expanding product launches, is expected to drive sales of expectorant drugs across the globe. Rising research and development activities and regulatory approvals will increase in the next few years,” opines Sabyasachi Ghosh, Associate Vice President at Future Market Insights (FMI).
Market Competition
Manufacturers are turning to discreet and innovative expectorant drugs to meet consumer demands. Therefore, brand promotion takes place on a parallel path. The major key players mostly rely on organic and inorganic growth strategies such as product launches, acquisitions, and collaborations. Some of the key developments are as follows:
Key Developments:
- In August 2023, Marksans Pharma secured approval from the US Food and Drug Administration (FDA) on its Abbreviated New Drug Application (ANDA) for Guaifenesin Extended-Release Tablets, 600 mg and 1200 mg (OTC). Guaifenesin extended-release tablets remove mucus from the bronchial passageways and improve coughing by loosening mucus and thinning bronchial secretions.
- In November 2022, During the flu season of 2022, a clean medicine company Genexa, the first to remove all artificially derived inactive ingredients from its products, announced the adult-only cough suppressant and expectorant Cough and chest Congestion that temporarily controls coughs, relieves chest congestion, and thins and loosens mucus with its maximum strength cough suppressant and expectorant.
Unlock Tailored Insights: Customize Your Report for Maximum Impact:https://www.futuremarketinsights.com/customization-available/rep-gb-18502
Key Segments:
By Drug Type:
- Secretion Enhancer
- Potassium Citrate
- Potassium Iodide
- Sodium Citrate
- Guaiphenesin
- Ammonium Chloride
- Others
- Mucolytics
- Bromhexine
- Ambroxol
- Acetyl Cysteine
- Carbocisteineurine
By Dosage Form:
- Oral Solid
- Powder & Granules
- Tablet
- Capsule
- Lozenge
- Oral Liquid
- Syrup
- Solution
- Suspension
- Elixir
- Inhalant
By Product Type:
- Over-The-Counter (OTC)
- Prescription Drug
By Distribution Channel:
- Hospital Pharmacies
- Retail Store
- Drug Store
- Online Pharmacies
By Region:
- North America
- Latin America
- Europe
- East Asia
- South Asia
- Oceania
- The Middle East and Africa
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
